Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Public Health Service of Madrid | OTHER |
Not provided
Not provided
Not provided
Not provided
A three-branch multi-center randomized clinical trial to be conducted in 6 public Primary Care centers located in the city of Madrid (Spain). A total of 180 older adults (>=70 years old) presenting with declines in the intrinsic capacity (IC) locomotion domain will be recruited in the participating centers. They will be randomized in a 1:1:1 ratio to a center-based supervised Vivifrail multicomponent exercise (MCE) program, a home-based non-supervised Vivifrail MCE program, or to a control group. The intervention consists of thrice-a-week exercise sessions encompassing strength, aerobic, flexibility, and balance and gait training tailored to the individual's baseline functional ability. IC will be assessed through its operational domains following ICOPE guidelines at baseline and 6 and 12 weeks after the start of the intervention. Secondarily, effects on frailty status and health-related quality of life will be evaluated.
This study might bring new evidence around the ICOPE recommendation on the Vivifrail MCE for the management of IC locomotion declines in Primary Care for the first time. Gaining insight on exercise interventions for IC promotion/maintenance will reinforce current recommendations and contribute to the development of real-world strategies for healthy aging promotion.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Supervised Vivifrail (S-ViF) | Experimental | A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Once-per-week, subjects assigned to this group will attend the primary care center to execute one of the three exercise sessions per week under the supervision of the physical therapist. |
|
| Non-supervised Vivifrail Group (NS-ViF) | Experimental | A 12-week intervention program that consists of walking every day (the time is individually adjusted) and exercising 3 times a week. Shared features of the different programs are the inclusion of resistance, cardiovascular, balance and flexibility components. All exercises will be individually tailored. Subjects assigned to this group will follow a domiciliary-based program and they will not attend the primary care center to execute the exercises. |
|
| Control group (UCG) | No Intervention | Subjects will receive usual care following prevention protocols of Primary Care Services in Madrid. Concisely, the benefits of physical activity are individually explained and subjects are advised to walk as much as possible with the aim of reaching at least 30 minutes a day, 5 days a week, following the recommendations of the World Health Organization. No structured exercise-based interventions are programmed in this group. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vivifrail multicomponent exercise program | Other | Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12. Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased. Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times. Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline to 12-weeks in the Short Physical Performance Battery (SPPB) score | Short Physical Performance Battery score measuring balance, lower extremity strength, and functional capacity in older adults. Minimum 0, maximum 12 (best) | From baseline (T0) to 12-weeks (T2) |
| Change from baseline to 6-weeks in the Short Physical Performance Battery (SPPB) score | Short Physical Performance Battery score measuring balance, lower extremity strength, and functional capacity in older adults. Minimum 0, maximum 12 (best) | From baseline (T0) to 6-weeks (T1) |
| Change from 12-weeks to 24-weeks in the Short Physical Performance Battery (SPPB) score | Short Physical Performance Battery score measuring balance, lower extremity strength, and functional capacity in older adults. Minimum 0, maximum 12 (best) | From 12-weeks (T2) to 24-weeks (T3) |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline to 12-weeks in the Montreal Cognitive Assessment (MoCA) score | Cognitive function (memory, language, attention, executive function, visuospatial and orientation). Minimum 0, maximum 30 (best) | From baseline (T0) to 12-weeks (T2) |
| Change from baseline to 6-weeks in the Montreal Cognitive Assessment (MoCA) score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Maria-Jose Gimenez, PhD | Contact | +34629174335 | mariajose.gimenez@universidadeuropea.es |
| Name | Affiliation | Role |
|---|---|---|
| Maria-Jose Gimenez, PhD | European University | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10811152 | Background | Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, Studenski S, Berkman LF, Wallace RB. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000 Apr;55(4):M221-31. doi: 10.1093/gerona/55.4.m221. |
| Label | URL |
|---|---|
| The Vivifrail multicomponent exercise program - Home page | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Three-branch multi-center randomized clinical trial with 1:1:1 allocation to a center-based supervised Vivifrail MCE, a home-based non-supervised Vivifrail MCE program, or to a control group.
Not provided
Not provided
Physical therapists in charge of the intervention will not be endpoint's evaluators. Participants will be informed and encouraged not to disclose their assignment to the endpoints' evaluators, which will remain blinded to individual's membership. Investigators responsible for the statistical analysis will be blinded.
|
Cognitive function (memory, language, attention, executive function, visuospatial and orientation). Minimum 0, maximum 30 (best) |
| From baseline (T0) to 6-weeks (T1) |
| Change from 12 to 24-weeks in the Montreal Cognitive Assessment (MoCA) score | Cognitive function (memory, language, attention, executive function, visuospatial and orientation). Minimum 0, maximum 30 (best) | From 12-weeks (T2) to 24-weeks (T3) |
| Change from baseline to 12-weeks in the Geriatric Depression Scale (GDS-15) | Depressive symptoms measured with the Geriatric Depression Scale (GDS-15), minimum 0, maximum 15 (worse) | From baseline (T0) to 12-weeks (T2) |
| Change from baseline to 6-weeks in the Geriatric Depression Scale (GDS-15) | Depressive symptoms measured with the Geriatric Depression Scale (GDS-15), minimum 0, maximum 15 (worse) | From baseline (T0) to 6-weeks (T1) |
| Change from 12-weeks to 24-weeks in the Geriatric Depression Scale (GDS-15) | Depressive symptoms measured with the Geriatric Depression Scale (GDS-15), minimum 0, maximum 15 (worse) | From 12 weeks (T2) to 24-weeks (T3) |
| Change from baseline (T0) to 12-weeks (T2) in the Mini-Nutritional Assessment -Short Form (MNA-SF) | Risk of malnutrition measured with the Mini-Nutritional Assessment -Short Form (MNA-SF), minimum 0, maximum 14 (best) | From baseline (T0) to 12-weeks (T2) |
| Change from baseline (T0) to 6-weeks (T1) in the Mini-Nutritional Assessment -Short Form (MNA-SF) | Risk of malnutrition measured with the Mini-Nutritional Assessment -Short Form (MNA-SF), minimum 0, maximum 14 (best) | From baseline (T0) to 6-weeks (T1) |
| Change from 12-weeks (T2) to 24-weeks (T3) in the Mini-Nutritional Assessment -Short Form (MNA-SF) | Risk of malnutrition measured with the Mini-Nutritional Assessment -Short Form (MNA-SF), minimum 0, maximum 14 (best) | From 12-weeks (T2) to 24-weeks (T3) |
| Change in the isometric handgrip strength from baseline (T0) to 12-weeks (T2) | Best attempt of the isometric handgrip strength (kg) of the dominant hand evaluated by a hand-held dynamometer | From baseline (T0) to 12-weeks (T2) |
| Change in the isometric handgrip strength from baseline (T0) to 6-weeks (T1) | Best attempt of the isometric handgrip strength (kg) of the dominant hand evaluated by a hand-held dynamometer | From baseline (T0) to 6-weeks (T1) |
| Change in the isometric handgrip strength from 12-weeks (T2) to 24-weeks (T3) | Best attempt of the isometric handgrip strength (kg) of the dominant hand evaluated by a hand-held dynamometer | From 12-weeks (T2) to 24-weeks (T3) |
| Change in visual capacity from baseline (T0) to 12-weeks (T2) | Distance and near vision assessed with WHO simple eye charts | From baseline (T0) to 12-weeks (T2) |
| Change in visual capacity from baseline (T0) to 6-weeks (T1) | Distance and near vision assessed with WHO simple eye charts | From baseline (T0) to 6-weeks (T1) |
| Change in visual capacity from 12-weeks (T2) to 24-weeks (T3) | Distance and near vision assessed with WHO simple eye charts | From 12-weeks (T2) to 24-weeks (T3) |
| Change in hearing capacity from baseline (T0) to 12-weeks (T2) | HearWHO App consisting of an automated digit-in-noise test | From baseline (T0) to 12-weeks (T2) |
| Change in hearing capacity from baseline (T0) to 6-weeks (T1) | HearWHO App consisting of an automated digit-in-noise test | From baseline (T0) to 6-weeks (T1) |
| Change in hearing capacity from 12-weeks (T2) to 24-weeks (T3) | HearWHO App consisting of an automated digit-in-noise test | From 12-weeks (T2) to 24-weeks (T3) |